144 results on '"Ryan, Meagan"'
Search Results
2. KRASG12C-independent feedback activation of wild-type RAS constrains KRASG12C inhibitor efficacy
3. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment
4. First Responders and Mental Health
5. WNT Activates the AAK1 Kinase to Promote Clathrin-Mediated Endocytosis of LRP6 and Establish a Negative Feedback Loop
6. A Concept-Based Approach to Building Clinical Judgment in Nursing
7. A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution
8. Therapeutic strategies to target RAS-mutant cancers
9. USP6 oncogene promotes Wnt signaling by deubiquitylating Frizzleds
10. Should fitness watches be regulated as medical devices?
11. Rural transition to practice: A phenomenological analysis of the new graduate nurses’ experience
12. Figure S4 from ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma
13. Supplementary Figure 4 from GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB
14. Data from ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma
15. Supplementary Figure 7 from GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB
16. Data from Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation
17. Supplementary Figure 8 from GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB
18. Supplementary Figure 5 from GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB
19. Supplementary Data from Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation
20. Supplementary Figure 1 from GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB
21. Supplementary Figure 2 from GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB
22. Data from GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB
23. Supplementary Methods from GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB
24. Supplementary Figure 9 from GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB
25. Supplementary Figure 6 from GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB
26. Supplementary Figure 3 from GSK-3α Promotes Oncogenic KRAS Function in Pancreatic Cancer via TAK1–TAB Stabilization and Regulation of Noncanonical NF-κB
27. Supplemental Figure Legends from ERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma
28. Targeting RAS-mutant Cancers: Is ERK the Key?
29. Supplementary Figure 8 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
30. Supplementary Figure 9 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
31. Supplementary Figure 7 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
32. Supplementary Figure 1 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
33. Supplementary Figure 2 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
34. Supplementary Figure 3 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
35. Supplementary Figure 5 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
36. Supplementary Figure 4 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
37. Supplementary Figure 6 from Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
38. Extracellular Signal-regulated Kinase (ERK) Phosphorylates Histone Deacetylase 6 (HDAC6) at Serine 1035 to Stimulate Cell Migration
39. Cell-Type-Specific Epigenetic Priming of Gene Expression in Nucleus Accumbens by Cocaine
40. Signing and witnessing documents: Execution requirements for Australian companies
41. CDDO-Me, a synthetic triterpenoid, inhibits expression of IL-6 and Stat3 phosphorylation in multi-drug resistant ovarian cancer cells
42. Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation
43. Implementing social media into nursing education
44. Abstract B50: ERK MAPK inhibition enhances the immunogenicity of KRAS-mutant colorectal cancer
45. Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition
46. Use of in situ isopropoxide protection in the metal-halogen exchange of arylboronates
47. Abstract A129: Vertical inhibition overcomes adaptive resistance to KRASG12Cinhibition
48. First Responders and Mental Health
49. AAK1 inhibits WNT signaling by promoting clathrin-mediated endocytosis of LRP6
50. A Transcription-uncoupled Negative Feedback Loop for the 1 WNT Pathway: WNT Activates the AAK1 Kinase to Promote Clathrin-mediated Endocytosis of LRP6
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.